Thirteen IPOs raised a combined $7.3 billion in April, joined by two direct listings. While surging volatility in March weighed on new issuance early on, activity ended in line with April’s 10-year historical average by deal count (15) but well above by...read more
Kailera Therapeutics, a phase 3 biotech developing injectable and oral GLP-1 agonists for obesity, raised $625 million by offering 39.1 million shares at $16, the high end of the $14 to $16 range. The company originally planned to offer 33.3 million shares at...read more
Kailera Therapeutics, a Phase 3 biotech developing injectable and oral GLP-1s for obesity, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $500 million by offering 33.3 million shares at a price range of $14 to $16. Certain...read more
Renaissance Capital’s April IPO Market Update
Thirteen IPOs raised a combined $7.3 billion in April, joined by two direct listings. While surging volatility in March weighed on new issuance early on, activity ended in line with April’s 10-year historical average by deal count (15) but well above by...read more
US IPO Weekly Recap: IPO calendar heats up as AI chipmaker Cerebras rejoins the public pipeline
Cerebras...read more
Obesity biotech Kailera Therapeutics prices upsized IPO at $16 high end
Kailera Therapeutics, a phase 3 biotech developing injectable and oral GLP-1 agonists for obesity, raised $625 million by offering 39.1 million shares at $16, the high end of the $14 to $16 range. The company originally planned to offer 33.3 million shares at...read more
Obesity biotech Kailera Therapeutics sets terms for $500 million IPO
Kailera Therapeutics, a Phase 3 biotech developing injectable and oral GLP-1s for obesity, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $500 million by offering 33.3 million shares at a price range of $14 to $16. Certain...read more